Q3 Earnings Forecast for Humacyte Issued By HC Wainwright

Humacyte, Inc. (NASDAQ:HUMA) – Stock analysts at HC Wainwright issued their Q3 2024 earnings estimates for Humacyte in a report issued on Tuesday, November 5th. HC Wainwright analyst V. Bernardino anticipates that the company will earn ($0.26) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Humacyte’s Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.28) EPS, FY2025 earnings at ($0.76) EPS, FY2026 earnings at ($0.17) EPS and FY2027 earnings at $0.24 EPS.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04).

A number of other equities analysts have also weighed in on HUMA. TD Cowen restated a “buy” rating and set a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Benchmark restated a “buy” rating and set a $15.00 target price on shares of Humacyte in a research report on Thursday, October 10th. Piper Sandler set a $6.00 target price on shares of Humacyte and gave the stock a “neutral” rating in a research report on Friday, October 18th. Finally, BTIG Research reiterated a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $11.00.

Humacyte Trading Down 3.1 %

Shares of NASDAQ:HUMA opened at $5.26 on Thursday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 5.41. The firm has a fifty day moving average price of $5.47 and a 200 day moving average price of $6.11. Humacyte has a fifty-two week low of $2.08 and a fifty-two week high of $9.97.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Thrivent Financial for Lutherans purchased a new position in Humacyte in the 3rd quarter worth about $712,000. Victory Capital Management Inc. increased its stake in Humacyte by 551.6% in the 3rd quarter. Victory Capital Management Inc. now owns 76,896 shares of the company’s stock worth $418,000 after buying an additional 65,095 shares during the period. Concurrent Investment Advisors LLC purchased a new position in Humacyte in the 3rd quarter worth about $75,000. China Universal Asset Management Co. Ltd. increased its stake in Humacyte by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock worth $125,000 after buying an additional 8,965 shares during the period. Finally, Private Advisor Group LLC increased its stake in Humacyte by 1.8% in the 3rd quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock worth $2,030,000 after buying an additional 6,510 shares during the period. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Insider Buying and Selling at Humacyte

In other news, Director Brady W. Dougan sold 352,112 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total value of $2,235,911.20. Following the sale, the director now owns 3,677,262 shares of the company’s stock, valued at approximately $23,350,613.70. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Brady W. Dougan sold 352,112 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total value of $2,235,911.20. Following the sale, the director now owns 3,677,262 shares of the company’s stock, valued at approximately $23,350,613.70. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Kathleen Sebelius sold 5,182 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total transaction of $27,982.80. Following the completion of the sale, the director now directly owns 40,276 shares in the company, valued at approximately $217,490.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,084,153 shares of company stock worth $6,869,996 over the last 90 days. 11.20% of the stock is owned by insiders.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.